CNS Pharmaceuticals (CNSP) vs Moleculin Biotech (MBRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Moleculin Biotech is the larger company by market cap ($8.6 million vs $7.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNSP | MBRX |
|---|---|---|
| Share price | $5.35 | $0.424 |
| Market cap | $7.82M | $8.64M |
| 1-day change | -1.47% | -3.39% |
| P/E ratio (TTM) | — | 0.05 |
| EPS (TTM) | $-17.90 | $8.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.54 | $15.75 |
| 52-week low | $1.90 | $0.161 |
| Distance from 52-week high | -49.24% | -97.31% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +86.92% | +2730.19% |
| Average volume | 6.40K | 1.29M |
| Shares outstanding | 1.46M | 20.39M |
| Employees | 8 | 17 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About CNS Pharmaceuticals
CNSP stock →CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors.
Healthcare · Biotechnology · 8 employees
About Moleculin Biotech
MBRX stock →Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
Healthcare · Biotechnology · 17 employees
CNSP vs MBRX FAQ
Which is bigger, CNS Pharmaceuticals or Moleculin Biotech?
Moleculin Biotech (MBRX) is larger, with a market capitalization of $8.64M compared with $7.82M for CNS Pharmaceuticals (CNSP).
Are CNS Pharmaceuticals and Moleculin Biotech in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.